Hologic Management

Management criteria checks 3/4

Hologic's CEO is Steve MacMillan, appointed in Dec 2013, has a tenure of 10.92 years. total yearly compensation is $15.56M, comprised of 7.6% salary and 92.4% bonuses, including company stock and options. directly owns 1.03% of the company’s shares, worth $187.69M. The average tenure of the management team and the board of directors is 3.8 years and 7.9 years respectively.

Key information

Steve MacMillan

Chief executive officer

US$15.6m

Total compensation

CEO salary percentage	7.6%
CEO tenure	10.9yrs
CEO ownership	1.0%
Management average tenure	3.8yrs
Board average tenure	7.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve MacMillan's remuneration changed compared to Hologic's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 29 2024	n/a	n/a	US$702m
Mar 30 2024	n/a	n/a	US$467m
Dec 30 2023	n/a	n/a	US$515m
Sep 30 2023	US$16m	US$1m	US$456m
Jul 01 2023	n/a	n/a	US$484m
Apr 01 2023	n/a	n/a	US$753m
Dec 31 2022	n/a	n/a	US$990m
Sep 24 2022	US$14m	US$1m	US$1b
Jun 25 2022	n/a	n/a	US$2b
Mar 26 2022	n/a	n/a	US$2b
Dec 25 2021	n/a	n/a	US$2b
Sep 25 2021	US$15m	US$1m	US$2b
Jun 26 2021	n/a	n/a	US$2b
Mar 27 2021	n/a	n/a	US$2b
Dec 26 2020	n/a	n/a	US$1b
Sep 26 2020	US$14m	US$1m	US$1b
Jun 27 2020	n/a	n/a	US$497m
Mar 28 2020	n/a	n/a	US$453m
Dec 28 2019	n/a	n/a	US$84m
Sep 28 2019	US$12m	US$1m	-US$204m
Jun 29 2019	n/a	n/a	-US$30m
Mar 30 2019	n/a	n/a	-US$11m
Dec 29 2018	n/a	n/a	-US$419m
Sep 29 2018	US$42m	US$1m	-US$111m

Compensation vs Market: Steve's total compensation ($USD15.56M) is above average for companies of similar size in the UK market ($USD5.74M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.

CEO

Steve MacMillan (60 yo)

10.9yrs

Tenure

US$15,555,032

Compensation

Mr. Stephen P. MacMillan, also known as Steve, serves as an Independent Chairman of the Board at Illumina, Inc. from June 02, 2023. He has been the Chairman of the Board at Hologic Inc. since June 17, 2015...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stephen MacMillan	Chairman	10.9yrs	US$15.56m	1.03% $ 187.7m
Karleen Oberton	Chief Financial Officer	6.3yrs	US$3.93m	0.045% $ 8.1m
Essex Mitchell	Chief Operating Officer	less than a year	US$2.17m	0.013% $ 2.5m
John Griffin	General Counsel	9.8yrs	US$3.34m	0.079% $ 14.4m
Jan Verstreken	Group President of International	no data	US$3.52m	0.045% $ 8.2m
Paul Malenchini	Chief Information Officer	3.3yrs	no data	no data
Ryan Simon	Vice President of Investor Relations	no data	no data	no data
Diana De Walt	Senior Vice President of Global Human Resources	less than a year	no data	no data
Monica Berthelot	VP & Chief of Staff	10.8yrs	no data	no data
Erik Anderson	Division President of Breast & Skeletal Health Solutions	4.3yrs	no data	0.010% $ 1.9m
Jennifer Schneiders	President of Diagnostics Solutions	1.6yrs	no data	0.0054% $ 991.3k
Scott Christensen	Senior Vice President of Global Supply Chain	1.1yrs	no data	no data

3.8yrs

Average Tenure

56yo

Average Age

Experienced Management: 0J5Q's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephen MacMillan	Chairman	10.9yrs	US$15.56m	1.03% $ 187.7m
Scott Garrett	Independent Director	11.5yrs	US$339.96k	0.018% $ 3.3m
Sally Crawford	Independent Director	17.1yrs	US$374.96k	0.057% $ 10.3m
Stacey Stewart	Independent Director	1.8yrs	US$338.44k	0.000070% $ 12.8k
Ludwig Hantson	Independent Director	6yrs	US$319.96k	0.0025% $ 458.2k
Charles Dockendorff	Independent Director	7.5yrs	US$344.96k	0.0066% $ 1.2m
Christiana Stamoulis	Independent Director	13yrs	US$319.96k	0.019% $ 3.5m
Amy Wendell	Lead Independent Director	7.9yrs	US$319.96k	0.0076% $ 1.4m
Nanaz Mohtashami	Independent Director	1.2yrs	US$128.96k	0.00032% $ 58.4k

7.9yrs

Average Tenure

61yo

Average Age

Experienced Board: 0J5Q's board of directors are considered experienced (7.9 years average tenure).

Hologic Management

Management criteria checks 3/4

Key information

Recent management updates

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Insider recently sold US$200k worth of stock

Hologic, Inc., Annual General Meeting, Mar 09, 2023

Recent updates

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Fiscal Year of 2025

Hologic, Inc. (NasdaqGS:HOLX) agreed to acquire Gynesonics, Inc. for $350 million.

Hologic, Inc. to Report Q4, 2024 Results on Nov 04, 2024

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,500 million worth of its shares.

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Third quarter 2024 earnings released: EPS: US$0.83 (vs US$0.16 loss in 3Q 2023)

Hologic, Inc. (NasdaqGS:HOLX) completed the acquisition of Endomagnetics Ltd. for approximately $310 million.

Hologic, Inc. to Report Q3, 2024 Results on Jul 29, 2024

Now 20% undervalued after recent price drop

Now 20% undervalued

Second quarter 2024 earnings released: EPS: US$0.72 (vs US$0.88 in 2Q 2023)

Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024

Now 21% undervalued

Hologic, Inc. (NasdaqGS:HOLX) signed a definitive agreement to acquire Endomagnetics Ltd. for approximately $310 million.

Hologic, Inc. to Report Q2, 2024 Results on May 02, 2024

Now 22% undervalued

Hologic, Inc. and Biotheranostics, Inc. Announces Newly Published Study Results Reveal That Use of the Breast Cancer Index®? Test

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024

First quarter 2024 earnings released: EPS: US$1.03 (vs US$0.76 in 1Q 2023)

Hologic, Inc. Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System

Hologic, Inc., Annual General Meeting, Mar 07, 2024

Namal Nawana Announces Not to Stand for Re-Election to the Board of Hologic, Inc

Now 21% undervalued

Hologic, Inc. Provides Revenue Guidance for the First Quarter of 2024

Hologic, Inc. to Report Q1, 2024 Results on Feb 01, 2024

Hologic, Inc. Promotes Essex D. Mitchell to Chief Operating Officer

Hologic, Inc. Provides Earnings Guidance for the First Quarter and Full-Year Fiscal 2024

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $500 million worth of its shares.

Full year 2023 earnings released: EPS: US$1.85 (vs US$5.18 in FY 2022)

Hologic, Inc. to Report Q4, 2023 Results on Nov 09, 2023

Nanaz Mohtashami Elected to Hologic, Inc.'S Board of Directors

Hologic, Inc. Reports Impairment Charges for the Third Quarter Ended July 1, 2023

New minor risk - Earnings quality

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$0.91 profit in 3Q 2022)

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Hologic, Inc. to Report Q3, 2023 Results on Jul 31, 2023

Hologic, Inc. Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay

Insider recently sold US$200k worth of stock

Second quarter 2023 earnings released: EPS: US$0.88 (vs US$1.81 in 2Q 2022)

Hologic, Inc. Announces Approval of NovaSure V5 Global Endometrial Ablation Device in Canada and Europe

First quarter 2023 earnings released: EPS: US$0.76 (vs US$1.97 in 1Q 2022)

Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Hologic, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Hologic, Inc., Annual General Meeting, Mar 09, 2023

Hologic, Inc. Revises Revenue Results for the First Quarter of Fiscal 2023

Hologic, Inc. to Report Q1, 2023 Results on Feb 01, 2023

Insider recently sold US$126k worth of stock

Hologic, Inc. Appoints Stacey D. Stewart to the Board of Directors, Effective January 2, 2023

Hologic, Inc. and Biotheranostics, Inc. Announce New Data Present At SABCS 2022

Chairman recently sold US$2.5m worth of stock

Full year 2022 earnings released: EPS: US$5.18 (vs US$7.28 in FY 2021)

Chairman recently sold US$3.3m worth of stock

Insufficient new directors

Full year 2022 earnings released: EPS: US$5.18 (vs US$7.28 in FY 2021)

Hologic, Inc. Provides Earnings Guidance for the First Quarter Ending December 31, 2022 and Year Ending September 30, 2023

Hologic, Inc. to Report Q4, 2022 Results on Oct 31, 2022

Hologic, Inc. (NasdaqGS:HOLX) announces an Equity Buyback for $1,000 million worth of its shares.

Hologic, Inc. Announces Separation of Sean S. Daugherty as President, Effective September 30, 2022

U.S. Court of Appeals for the Federal Circuit Affirms Ruling on Minerva Surgical, Inc. and Hologic, Inc. Case

Third quarter 2022 earnings released: EPS: US$0.91 (vs US$1.05 in 3Q 2021)

Hologic, Inc. Provides Earnings Guidance for the Fourth Quarter Ending September 24, 2022

Hologic, Inc. Announces Two New Respiratory Assays for the Detection of COVID-19, Flu A, Flu B and RSV

Hologic, Inc. to Report Q3, 2022 Results on Jul 27, 2022

Group President of International recently sold US$512k worth of stock

Hologic Announces FDA Approval of Aptima CMV Quant Assay for Human Cytomegalovirus

Insider recently sold US$162k worth of stock

Second quarter 2022 earnings released: EPS: US$1.81 (vs US$2.40 in 2Q 2021)

Hologic, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Insufficient new directors